Man Who Received First Modified Pig Heart Transplant Dies

March 9, 2022 -- David Bennett Sr., the 57-year-old patient with terminal heart disease who became the first person to receive a genetically modified pig heart, has died.

Bennett passed away Tuesday, according to a statement from the University of Maryland Medical Center in Baltimore, where the transplant was performed.

Bennett received the transplant on Jan. 7 and lived for 2 months after it.

Although not giving the exact cause of his death, the medical center said Bennett's condition began getting worse several days before his death.

When it became clear that he would not recover, he was given compassionate palliative care and was able to communicate with his family during his final hours.

"We are devastated by the loss of Mr. Bennett. He proved to be a brave and noble patient who fought all the way to the end. We extend our sincerest condolences to his family," Bartley P. Griffith, MD, who performed the transplant, said in the statement.

"We are grateful to Mr. Bennett for his unique and historic role in helping to contribute to a vast array of knowledge to the field of xenotransplantation," which is the process of transplanting organs between different species, said Muhammad M. Mohiuddin, MD, director of the cardiac xenotransplantation program at University of Maryland School of Medicine.

Before receiving the genetically modified pig heart, Bennett needed mechanical support to stay alive but was rejected for a standard heart transplant at the University of Maryland Medical Center and other centers.

After the surgery, the transplanted pig heart performed well for several weeks without any signs of rejection. Bennett was able to spend time with his family and do physical therapy to help regain strength.

"This organ transplant demonstrated for the first time that a genetically modified animal heart can function like a human heart without immediate rejection by the body," the medical center said in a statement 3 days after the surgery.

Thanks to Bennett, "we have gained invaluable insights learning that the genetically modified pig heart can function well within the human body while the immune system is adequately suppressed," said Mohiuddin.

"We remain optimistic and plan on continuing our work in future clinical trials," he said.

Bennett’s son, David Bennett Jr, said the family is "profoundly grateful for the life-extending opportunity" given to his father by the "stellar team" at the University of Maryland School of Medicine and the University of Maryland Medical Center.

"We were able to spend some precious weeks together while he recovered from the transplant surgery, weeks we would not have had without this miraculous effort," Bennett Jr. said.

"We also hope that what was learned from his surgery will benefit future patients and hopefully one day, end the organ shortage that costs so many lives each year," he said.